-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Tops Q1 EPS by 6c
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Misses Q4 EPS by 214c ; Offers Guidance
-
-
-
-
-
-
-
German court grants HALOZYME injunction against Merck's Keytruda SC
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $90 at Benchmark Following Strong Earnings, Guidance
-
-
-
-
-
-
-
Goldman Sachs Resumes Halozyme Therapeutics (HALO) at Neutral
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Halozyme Therapeutics (HALO)
-
416,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

